MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
Express News | Medicinova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
Express News | MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
Express News | Medicinova Receives Notice of Allowance From United States Patent and Trademark Office for New Patent Covering Mn-001 for Triglyceride Synthesis in the Liver
MediciNova | 10-Q: Q3 2024 Earnings Report
MediciNova: Q3 Earnings Snapshot